Pacira BioSciences
PCRX
218 hedge funds and large institutions have $1.89B invested in Pacira BioSciences in 2019 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 85 increasing their positions, 55 reducing their positions, and 30 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 55
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
33% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 30
23% more call options, than puts
Call options by funds: $9.61M | Put options by funds: $7.85M
20% more capital invested
Capital invested by funds: $1.57B → $1.89B (+$318M)
5.03% more ownership
Funds ownership: 100.34% → 105.37% (+5%)
4% more funds holding
Funds holding: 210 → 218 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$37M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$31.5M |
| 3 |
PC
Paulson & Co
New York
|
+$30.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.5M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$40.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$36.2M |
| 3 |
HM
HealthCor Management
New York
|
-$26.9M |
| 4 |
Goldman Sachs
New York
|
-$12.6M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$6.77M |
PCRX Hedge Fund Activity: Q2 2019 in Review
218 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2019, worth a combined $1.89B — up 20% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new PCRX positions and 30 closed out — a net gain of 10 holders — while 85 added to existing stakes and 55 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $37M. The largest seller was Armistice Capital, exiting entirely with an estimated $40.8M sold.
- 218 institutional investors held Pacira BioSciences (PCRX) as of Q2 2019, up from 210 in Q1 2019.
- Funds reported $1.89B of Pacira BioSciences stock for Q2 2019, up 20% quarter-over-quarter.
- 40 funds opened new Pacira BioSciences positions in Q2 2019 and 30 closed out, a net change of +10 holders.
- The largest Pacira BioSciences buyer in Q2 2019 was Nuveen, an estimated $37M added.
- The largest Pacira BioSciences seller in Q2 2019 was Armistice Capital, an estimated $40.8M sold.
Based on aggregated 13F filings for Q2 2019.